Analysis of Therapeutic Effect of Daggligin Combined with Irbesartan on Diabetes Nephropathy
Objective To analyze the clinical effect of daggligin+irbesartan in the treatment of diabetes nephropathy.Methods Ninety patients with diabetes nephropathy who were admitted to Linqu County People's Hospital from March 2022 to September 2023 were selected by target sampling method.According to different treatment methods,the patients were divided into a control group and an observation group,with forty-five cases in each group.The con-trol group was treated with irbesartan alone,while the observation group was treated with dapagliflozin+irbesartan.The levels of blood glucose,renal function indicators,incidence of adverse reactions,and treatment efficacy were com-pared between the two groups of patients.Results After treatment,the fasting blood glucose(5.52±0.41)mmol/L,2-hour postprandial blood glucose(7.01±0.69)mmol/L,and glycated hemoglobin(5.87±0.31)% in the observation group were lower than(6.02±0.59)mmol/L,(7.92±0.67)mmol/L,and(6.21±0.44)% in the control group,and the differences were statistically significant(t=4.668,6.347,4.237,all P<0.05).The renal function indicators of the observation group were superior to those of the control group,and the differences were statistically significant(all P<0.05).The inci-dence of adverse reactions in the observation group was lower than that in the control group,and the total effective rate of treatment was higher than that in the control group,the differences were statistically significant(both P<0.05).Con-clusion The combined treatment of daggligin and irbesartan has a significant effect on patients with diabetes nephropa-thy,which can improve the levels of blood glucose and renal function indicators,and has a high drug safety.
NETL
NSTL
万方数据
